Market Place
Sourcing Support
Lundbeck acquires all outstanding shares of Longboard Pharma
04 Dec 2024 //
PRESS RELEASE
Longboard Launches Phase 3 DEEp OCEAN Study for Bexicaserin in DEEs
12 Nov 2024 //
BUSINESSWIRE
Longboard Pharma Reports Q3 2024 Results & Corporate Updates
07 Nov 2024 //
BUSINESSWIRE
Denmark`s Lundbeck bets on epilepsy drug with $2.6 bln Longboard deal
15 Oct 2024 //
REUTERS
Longboard Pharmaceuticals Announces Inducement Grants Under Rule
04 Oct 2024 //
BUSINESSWIRE
Longboard Initiates Phase 3 Study In Dravet Syndrome
26 Sep 2024 //
BUSINESSWIRE
Longboard Pharmaceuticals Receives Rare Pediatric Designation
19 Sep 2024 //
BUSINESSWIRE
Longboard Reports Positive OLE Results For Bexicaserin In DEEs
08 Sep 2024 //
BUSINESSWIRE
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Rule
06 Sep 2024 //
BUSINESSWIRE
Longboard Pharmaceuticals To Attend Four Investor Conferences
28 Aug 2024 //
BUSINESSWIRE
Longboard Pharmaceuticals To Host Investor Event In New York On September 16
26 Aug 2024 //
BUSINESSWIRE
Longboard Pharmaceuticals To Present Data At European Epilepsy Congress
26 Aug 2024 //
BUSINESSWIRE
Longboard Pharmaceuticals Announces Inducement Grants
02 Aug 2024 //
BUSINESSWIRE
Longboard Pharmaceuticals Reports Q2 2024 Results And Updates
01 Aug 2024 //
BUSINESSWIRE
Longboard To Report Q2 2024 Results On August 1
29 Jul 2024 //
BUSINESSWIRE
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule
03 Jul 2024 //
BUSINESSWIRE
Longboard`s Bexicaserin Gets Breakthrough Therapy Designation
01 Jul 2024 //
BUSINESSWIRE
Longboard Pharmaceuticals Announces Positive Interim Results From The OLE
10 Jun 2024 //
BUSINESSWIRE
Longboard Announces Nasdaq Employee Inducement Grants
03 Jun 2024 //
BUSINESSWIRE
Beacon Biosignals Selected By Longboard Pharma For Epilepsy Understanding
13 May 2024 //
GLOBENEWSWIRE
Longboard Pharma Inducement Grants Under Nasdaq Rule
06 May 2024 //
BUSINESSWIRE
Longboard Reports Q1 2024 Results, Corporate Updates
02 May 2024 //
BUSINESSWIRE
Longboard to Present Data from the PACIFIC Study at the AAN Annual Meeting
03 Apr 2024 //
BUSINESSWIRE
Longboard Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
02 Apr 2024 //
BUSINESSWIRE
Longboard Pharmaceuticals Reports Full Year 2023 Financial Results
12 Mar 2024 //
BUSINESSWIRE
Longboard Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
01 Mar 2024 //
BUSINESSWIRE
Longboard Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
02 Feb 2024 //
BUSINESSWIRE
Longboard Pharma to Present at Two Upcoming Investor Conferences in February
01 Feb 2024 //
BUSINESSWIRE
Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock
08 Jan 2024 //
BUSINESSWIRE
Longboard Pharma Announces Pricing of Upsized Public Offering of Common Stock
03 Jan 2024 //
BUSINESSWIRE
Longboard’s shares triple as epilepsy med halves seizure rates
03 Jan 2024 //
FIERCE BIOTECH
Longboard Pharma Announces Positive Topline Data From Trial for Bexicaserin
02 Jan 2024 //
PRESS RELEASE
Longboard Pharma Announces Commencement of Public Offering of Common Stock
02 Jan 2024 //
BUSINESSWIRE
Longboard to Host Call to Discuss Data from the PACIFIC Study for Bexicaserin
01 Jan 2024 //
BUSINESSWIRE
Longboard Pharma to Host Call to Discuss Topline Data from the PACIFIC Study
01 Jan 2024 //
BUSINESSWIRE
Longboard Announces Initiation of First-in-Human Phase 1 Clinical Study of LP659
29 Nov 2023 //
BUSINESSWIRE
Longboard’s Presence at AES Meeting Reinforces Commitment to Epilepsy Community
21 Nov 2023 //
BUSINESSWIRE
Longboard Reports Third Quarter 2023 Financial Results
02 Nov 2023 //
BUSINESSWIRE
Longboard to Present at Three Upcoming Investor Conferences in November
01 Nov 2023 //
BUSINESSWIRE
Longboard Announces Speakers for Investor & Analyst Event in New York
05 Oct 2023 //
BUSINESSWIRE
Longboard to Host Investor & Analyst Event in New York on October 11, 2023
19 Sep 2023 //
BUSINESSWIRE
Longboard Pharmaceuticals to Participate in Three Upcoming Investor Conferences
31 Aug 2023 //
BUSINESSWIRE
Longboard Completes Enrollment of Phase 1b/2a PACIFIC Study Evaluating LP352
23 Aug 2023 //
BUSINESSWIRE
Longboard Pharmaceuticals to Present at Upcoming Investor Conferences
03 Aug 2023 //
BUSINESSWIRE
Longboard Pharmaceuticals Reports Second Quarter 2023 Financial Results
03 Aug 2023 //
BUSINESSWIRE
Longboard to Participate in Fireside Chat with Cantor on Friday, June 30, 2023
26 Jun 2023 //
BUSINESSWIRE
Longboard Pharmaceuticals Provides Corporate Update and Reports1Q 2023 FYR
09 May 2023 //
BUSINESSWIRE
Longboard to Present at the 22nd Annual Needham Virtual Healthcare Conference
11 Apr 2023 //
BUSINESSWIRE
Longboard Selects Societal CDMO to Support Clinical Development of LP352
05 Apr 2023 //
CONTRACT PHARMA
Longboard Pharmaceuticals Reports Full Year 2022 Financial Results
02 Mar 2023 //
BUSINESSWIRE
Longboard Pharmaceuticals to Report Full Year 2022 Financial Results
23 Feb 2023 //
BUSINESSWIRE
Longboard Announces Closing of Offering & Exercise of Underwriters’ Option
10 Feb 2023 //
BUSINESSWIRE
Longboard Pharma Announces Commencement of Public Offering of Common Stock
07 Feb 2023 //
BUSINESSWIRE
Longboard Pharmaceuticals Announces Pricing of Public Offering of Common Stock
07 Feb 2023 //
BUSINESSWIRE
Longboard reports positive data from Phase I LP352 clinical study
07 Dec 2022 //
CLINICALTRIALSARENA
Longboard Announces Positive Data from PI Evaluating Pharmacokinetics of LP352
05 Dec 2022 //
BUSINESSWIRE
Longboard’ Presence at AES Reinforces Commitment to Rare Epilepsy Community
29 Nov 2022 //
BUSINESSWIRE
Longboard Pharmaceuticals to Present at Guggenheim’s Healthcare Talk
08 Nov 2022 //
BUSINESSWIRE
Longboard Pharmaceuticals to Participate in the Cantor Neurology
29 Sep 2022 //
GLOBENEWSWIRE
Longboard Pharmaceuticals to Participate in Upcoming Investor Conferences
01 Sep 2022 //
GLOBENEWSWIRE
